Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Estradiol in ER Beta Positive Triple Negative Breast Cancer
NCT03941730Phase 2Active, not recruiting
- Sponsor
- Mayo Clinic
- Start
- Aug 2019
- Primary completion
- Jul 2024
- Modality
- Hormone, Biologic
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of estradiol in breast cancer, sponsored by Mayo Clinic. Primary endpoint: Clinical Benefit Rate at 173 days. Started Aug 2019; status: active, not recruiting.
02
Drugs
estradiol
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03941730.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03941730.